

# United States Senate

COMMITTEE ON FINANCE

WASHINGTON, DC 20510-6200

December 11, 2025

Dr. Pascal Soriot  
Executive Director and Chief Executive Officer  
AstraZeneca PLC  
1 Francis Crick Avenue  
Cambridge Biomedical Campus  
Cambridge CB2 0AA, UK

Dear Dr. Soriot:

On July 4, 2025, President Trump signed the Republican reconciliation bill (H.R. 1) into law. That bill included nearly \$900 billion in cuts to the Medicaid program, which will create disastrous consequences for state budgets, and, in turn, access to health care services for Americans all across the country. States have few options when it comes to filling the hole left by massive federal cuts – all of which lead to less access for patients. States can either cut provider rates, cut services, or cut eligibility for Medicaid – each of these options will make Americans sicker, force hospitals to close and cut services, and increase health care costs for all.

The deep Medicaid cuts in H.R. 1 have put states in the impossible position of trying to figure out how to keep our Medicaid programs afloat and ensure continued patient access across the health care system writ large. With that in mind, we write today to seek more information from AstraZeneca about which drugs are subject to the Medicaid components of your agreement with the Trump Administration and whether the prices you will make available on these drugs are actually lower than the net pricing states currently receive on the same products in Medicaid.

On October 10, 2025, you held a press conference with President Trump announcing that AstraZeneca would offer “most-favored nation” pricing on certain prescription drugs in Medicaid. It is clear that AstraZeneca stands to gain a lot from this agreement, including relief from tariffs and potential priority review of new drug applications at the Food and Drug Administration (FDA). The Trump Administration is also pressuring other countries, such as the U.K., to pay higher prices for drugs, which will further increase revenues for industry, even though it is unclear whether industry will be expected to proportionally lower pricing in the U.S.

It is difficult to discern, however, what patients in Medicaid and taxpayers stand to gain from your agreement with the Trump Administration. On November 6, 2025, CMS announced the Generating Cost Reductions for U.S. Medicaid Model (GENEROUS) model and released a corresponding request for applications from manufacturers. The GENEROUS model is a voluntary demonstration program under which CMS will negotiate supplemental rebates and

coverage terms on prescription drugs with participating manufacturers. The Trump Administration claims that these rebates will bring Medicaid drug costs closer to international pricing on covered outpatient drugs for states that choose to participate in the model. Presumably, manufacturers like AstraZeneca that have announced agreements with the Trump Administration will be able to effectuate the Medicaid components of those agreements through the GENEROUS model.

States won't benefit if GENEROUS model prices are essentially the same as current Medicaid net prices or higher. Medicaid already pays the lowest drug prices in the U.S., often in line with the prices paid in other wealthy countries. For example, a 2021 analysis by the Congressional Budget Office (CBO) found that the average net price of top-selling brand drugs in Medicaid was \$118, relative to an average price of \$343 in Medicare Part D.<sup>1</sup> Critical details about the GENEROUS model also remain unclear, including whether manufacturers can seek exemptions for the drugs where this model could potentially have the greatest impact. Furthermore, the RFA explicitly states that terms under CMS agreements with manufacturers can differ from the terms CMS just publicly released about the model. Thus, it is difficult to draw any firm conclusions about what pricing manufacturers will have to offer states under the model and on which drugs.

Attached to this letter, you will find a table listing brand drugs currently marketed by AstraZeneca and a list of AstraZeneca subsidiary and affiliate companies. We ask that AstraZeneca promptly respond by populating those tables and providing the following information:

1. Does AstraZeneca plan to effectuate the Medicaid components of its drug pricing agreement with the Trump Administration through the GENEROUS model? If not, please explain how AstraZeneca will effectuate its Medicaid drug pricing agreement with the Trump Administration.
2. During which calendar years does AstraZeneca plan to either participate in the GENEROUS model or otherwise offer agreed upon pricing to state Medicaid programs pursuant to your agreement with the Trump Administration?
3. Please populate Table 1 by:
  - a. Identifying which drugs in your current book of business are subject to the Medicaid part of your agreement with the Trump Administration and/or will be included in the GENEROUS model;
  - b. Providing the second lowest country specific average net price on each drug identified above over the last 12 months from the following countries: the United Kingdom, France, Germany, Italy, Canada, Japan, Denmark, and Switzerland<sup>2</sup>;

---

<sup>1</sup> CBO. A Comparison of Brand-Name Drug Prices Across Selected Federal Programs. February 2021. Available at: <https://www.cbo.gov/publication/57007>

<sup>2</sup> While we recognize that this price might not be the same as model pricing under the GENEROUS model, this pricing methodology appears to generally reflect what the Trump Administration in its request for applications from manufacturers is purporting to deliver states. Pricing information along these lines will presumably be released fairly broadly to states. Therefore, we think it is reasonable to ask manufacturers to release this information. It will be helpful for states to have this information in order to compare this price point to the pricing ultimately offered under the GENEROUS model and/or pursuant to your agreement with the Trump Administration.


- c. Providing the net price available to state Medicaid programs under your agreement with the Trump Administration and/or the GENEROUS model for each such drug identified above<sup>3</sup>; and
  - d. Confirming whether the price listed above is lower than the lowest net price AstraZeneca currently offers to any state Medicaid program for such drug (including both statutorily required rebates under the Medicaid Drug Rebate Program and any supplemental rebates).
- 4. Please populate Table 2 by:
  - a. Listing all drugs marketed in the United States under labels of AstraZeneca subsidiary or affiliate companies;
  - b. Identifying which drugs among those listed above are subject to the Medicaid part of your agreement with the Trump Administration and/or will be included in the GENEROUS model;
  - c. Providing the second lowest country specific average net price on each drug identified above over the last 12 months from the following countries: the United Kingdom, France, Germany, Italy, Canada, Japan, Denmark, and Switzerland;
  - d. Providing the net price available to state Medicaid programs under your agreement with the Trump Administration and/or the GENEROUS model for each such drug identified above; and
  - e. Confirming whether the price listed above is lower than the lowest net price AstraZeneca currently offers to any state Medicaid program for such drug (including both statutorily required rebates under the Medicaid Drug Rebate Program and any supplemental rebates).
- 5. If AstraZeneca is effectuating the Medicaid components of your agreement with the Trump Administration through a method other than the GENEROUS model:
  - a. Please explain how state Medicaid programs would receive any additional discounts or rebates on the relevant drugs.
  - b. In order to access any additional discounts on AstraZeneca drugs under the agreement, would state Medicaid programs need to agree to any conditions related to coverage, formulary placement, or utilization management for such drugs? If yes, would states have to opt into the agreement with respect to the entire bundle of drugs subject to the arrangement? Or could states make separate decisions with respect to each individual drug?
  - c. How would any additional discounts or rebates relate to the statutorily required rebates under the Medicaid Drug Rebate Program or supplemental rebates obtained by state Medicaid programs?

States need timely access to this information in order to make urgent state budgetary decisions due to the loss of Medicaid funding, including during special sessions and in preparation of budgets for the upcoming state fiscal year, and prioritize preserving patient access to health care. Therefore, we ask that you provide this information no later than January 30, 2026.


---

<sup>3</sup> As noted above, pricing information under the GENEROUS model and/or pursuant to manufacturer agreements with the Trump Administration will presumably be released fairly broadly to states. Therefore, we think it is reasonable to ask manufacturers to release this information.

Sincerely,



Ron Wyden  
United States Senator  
Ranking Member, Committee  
on Finance



Jeffrey A. Merkley  
United States Senator



Richard J. Durbin  
United States Senator




John Hickenlooper  
United States Senator




Christopher S. Murphy  
United States Senator



Amy Klobuchar  
United States Senator



Elizabeth Warren  
United States Senator



Michael F. Bennet  
United States Senator

**Table 1: Drugs Marketed Under AstraZeneca Label**

Drug Name	NDC Code	Indication(s)	In GENEROUS/ Agreement? (Y/N)	Second Lowest Country Specific Net Price	Medicaid Net Price Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
AIRSUPRA	0310- 9080-12					
AIRSUPRA	0310- 9080-28					
ANDEXXA	0310- 3200-04					
ANDEXXA	0310- 3200-05					
BEVESPI AEROSPHERE	0310- 4600-12					
BREZTRI	0310- 4616-12					
BREZTRI	0310- 4616-28					
BREZTRI	0310- 4616-39					
BRILINTA	0186- 0776-60					
BRILINTA	0186- 0777-08					
BRILINTA	0186- 0777-39					
BRILINTA	0186- 0777-60					
Budesonide and Formoterol Fumarate Dihydrate	0310- 7370-20					
Budesonide and Formoterol Fumarate Dihydrate	0310- 7372-20					

Drug Name	NDC Code	Indication(s)	In GENEROUS/ Agreement? (Y/N)	Second Lowest Country Specific Net Price	Medicaid Net Price Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
BYDUREON BCise	0310- 6540-04					
Byetta	0310- 6512-01					
Byetta	0310- 6524-01					
CALQUENCE	0310- 3512-60					
CALQUENCE	0310- 3512-95					
CALQUENCE	0310- 4513-60					
Crestor	0310- 7560-90					
Crestor	0310- 7570-90					
Crestor	0310- 7580-90					
Crestor	0310- 7590-30					
Daliresp	0310- 0088-28					
Daliresp	0310- 0088-39					
Daliresp	0310- 0095-30					
Daliresp	0310- 0095-90					
FARXIGA	0310- 6205-30					

Drug Name	NDC Code	Indication(s)	In GENEROUS/ Agreement? (Y/N)	Second Lowest Country Specific Net Price	Medicaid Net Price Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
FARXIGA	0310-6205-90					
FARXIGA	0310-6205-95					
FARXIGA	0310-6210-30					
FARXIGA	0310-6210-39					
FARXIGA	0310-6210-90					
FARXIGA	0310-6210-95					
FASENRA	0310-1730-30					
FASENRA	0310-1730-85					
FASENRA	0310-1745-01					
FASENRA	0310-1745-95					
FASENRA	0310-1830-30					
FASENRA	0310-1830-85					
FASLODEX	0310-0720-10					
IMFINZI	0310-4500-12					
IMFINZI	0310-4611-50					

Drug Name	NDC Code	Indication(s)	In GENEROUS/ Agreement? (Y/N)	Second Lowest Country Specific Net Price	Medicaid Net Price Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
IMJUDO	0310-4505-25					
IMJUDO	0310-4535-30					
IRESSA	0310-0482-30					
KOMBIGLYZ E	0310-6125-60					
KOMBIGLYZ E	0310-6135-30					
KOMBIGLYZ E	0310-6145-30					
KOSELUGO	0310-0610-28					
KOSELUGO	0310-0610-60					
KOSELUGO	0310-0625-28					
KOSELUGO	0310-0625-60					
KOSELUGO	0310-0635-60					
KOSELUGO	0310-0640-60					
LOKELMA	0310-1105-30					
LOKELMA	0310-1105-39					
LOKELMA	0310-1110-30					



Drug Name	NDC Code	Indication(s)	In GENEROUS/ Agreement? (Y/N)	Second Lowest Country Specific Net Price	Medicaid Net Price Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
LOKELMA	0310- 1110-39					
LOKELMA	0310- 1110-93					
Lynparza	0310- 0668-12					
Lynparza	0310- 0668-60					
Lynparza	0310- 0668-95					
Lynparza	0310- 0679-12					
Lynparza	0310- 0679-60					
Lynparza	0310- 0679-95					
Lynparza	0310- 0569-12					
Lynparza	0310- 0578-12					
Lynparza	0310- 0569-60					
Lynparza	0310- 0578-60					
NEXIUM	0186- 4050-01					
NEXIUM	0186- 4010-01					
NEXIUM	0186- 4020-01					

Drug Name	NDC Code	Indication(s)	In GENEROUS/ Agreement? (Y/N)	Second Lowest Country Specific Net Price	Medicaid Net Price Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
NEXIUM	0186- 4040-01					
NEXIUM	0186- 5020-31					
NEXIUM	0186- 5020-54					
NEXIUM	0186- 4025-01					
NEXIUM	0186- 5040-31					
NEXIUM	0186- 5040-54					
ONGLYZA	0310- 6100-30					
ONGLYZA	0310- 6100-90					
ONGLYZA	0310- 6105-30					
ONGLYZA	0310- 6105-90					
PULMICORT	0186- 0916-12					
PULMICORT	0186- 0917-06					
PULMICORT RESPULES	0186- 1988-04					
PULMICORT RESPULES	0186- 1989-04					
PULMICORT RESPULES	0186- 1990-04					

Drug Name	NDC Code	Indication(s)	In GENEROUS/ Agreement? (Y/N)	Second Lowest Country Specific Net Price	Medicaid Net Price Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
QTERN	0310- 6770-30					
QTERN	0310- 6780-30					
SAPHNELO	0310- 3040-00					
SEROQUEL	0310- 0271-10					
SEROQUEL	0310- 0272-10					
SEROQUEL	0310- 0274-60					
SEROQUEL	0310- 0275-10					
SEROQUEL	0310- 0278-10					
SEROQUEL	0310- 0279-10					
SEROQUEL	0310- 0280-60					
SEROQUEL	0310- 0281-60					
SEROQUEL	0310- 0282-60					
SEROQUEL	0310- 0283-60					
SEROQUEL	0310- 0284-60					
SYMBICORT	0186- 0370-20					

Drug Name	NDC Code	Indication(s)	In GENEROUS/ Agreement? (Y/N)	Second Lowest Country Specific Net Price	Medicaid Net Price Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
SYMBICORT	0186-0370-28					
SYMBICORT	0186-0372-20					
SYMBICORT	0186-0372-28					
SymlinPen	0310-6615-02					
SymlinPen	0310-6627-02					
TAGRISSO	0310-1349-30					
TAGRISSO	0310-1350-30					
TAGRISSO	0310-1350-95					
TAGRISSO	0310-1248-30					
TAGRISSO	0310-1251-30					
TRUQAP	0310-9500-01					
TRUQAP	0310-9501-01					
TRUQAP	0310-9501-96					
TRUQAP	0310-9500-02					
TRUQAP	0310-9501-02					

Drug Name	NDC Code	Indication(s)	In GENEROUS/ Agreement? (Y/N)	Second Lowest Country Specific Net Price	Medicaid Net Price Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
WAINUA	0310- 9400-01					
XIGDUO	0310- 6225-60					
XIGDUO	0310- 6250-30					
XIGDUO	0310- 6260-60					
XIGDUO	0310- 6260-95					
XIGDUO	0310- 6270-30					
XIGDUO	0310- 6280-30					
XIGDUO	0310- 6280-95					

**Table 2: Drugs Marketed Under AstraZeneca Subsidiary or Affiliate Labels**

<b>Company</b>	<b>List of Brand Drugs Marketed in the U.S. and Indications</b>	<b>List of Drugs in GENEROUS/ Agreement</b>	<b>Second Lowest Country Specific Net Price</b>	<b>Medicaid Net Price(s) Under Agreement/ GENEROUS</b>	<b>Lower than Current Net Price in Medicaid? (Y/N)</b>
<b>Acerta Pharma</b>					
<b>Achillion Pharmaceuticals Inc.</b>					
<b>Alexion Pharmaceuticals</b>					
<b>AlphaCore Pharma</b>					
<b>Amolyt Pharma Inc.</b>					
<b>Amylin Pharmaceuticals</b>					
<b>Ardea Biosciences</b>					
<b>Arrow Therapeutics Limited</b>					
<b>Aspire Therapeutics</b>					
<b>Astra Pharmaceuticals</b>					
<b>Caelum Biosciences Inc.</b>					
<b>Cambridge Antibody Technology Group Limited</b>					
<b>Cincor Pharma Inc.</b>					
<b>Fusion Pharmaceuticals</b>					
<b>Gotland Pharma</b>					
<b>Gracell</b>					

Company	List of Brand Drugs Marketed in the U.S. and Indications	List of Drugs in GENEROUS/ Agreement	Second Lowest Country Specific Net Price	Medicaid Net Price(s) Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
Icosavax, Inc.					
IPR Pharmaceuticals, Inc.					
KuDOS Pharmaceuticals					
LogicBio Therapeutics, Inc.					
MedImmune					
Neogene Therapeutics					
Omthera Pharmaceuticals, Inc.					
Optein, Inc.					
Pearl Therapeutics, Inc.					
Portola Pharmaceuticals					
Savoy Therapeutics Corp					
Sofotec GmbH5					
Syntimmune					
TeneoTwo, Inc.					